Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$8.57M$8.57Mno prior Q3 2016 on file Net Income-$41.87M-$41.87MN/M vs Q3 2016 EPS Diluted-$0.77-$0.77N/M vs Q3 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$40,540,000N/M Free Cash Flowderived-$40,535,000N/M Margins · derivedGross margin87.7%
Operating margin-482.0%
Net margin-488.4%
ended Sep 30, 2017 · filed Nov 6, 2017 · 37 d after period end